IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11439639 B1

PDFFull Text
Date of Patent:
Sep. 13, 2022

Filed:

Sep. 10, 2021

Pyrazine-containing compound

Applicant:

Calcimedica, Inc., La Jolla, CA (US);

Inventors:

Gonul Velicelebi, San Diego, CA (US);

Kenneth Stauderman, San Diego, CA (US);

Michael Dunn, La Jolla, CA (US);

Jack Roos, San Diego, CA (US);

Assignee:

CALCIMEDICA, INC., La Jolla, CA (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Yevgeny Valenrod

Int. Cl.
CPC ...
A61K 31/497 (2006.01); A61K 45/06 (2006.01); A61K 31/415 (2006.01); A61K 31/427 (2006.01); A61K 31/485 (2006.01); A61K 31/444 (2006.01); A61K 31/506 (2006.01); A61K 31/421 (2006.01); C07D 405/04 (2006.01); C07D 417/14 (2006.01); C07D 401/04 (2006.01); A61K 31/4155 (2006.01); C07D 417/10 (2006.01); A61K 31/4439 (2006.01); C07D 491/04 (2006.01); C07D 413/14 (2006.01); A61P 1/18 (2006.01);
U.S. Cl.
CPC ...
A61K 31/497 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/421 (2013.01); A61K 31/427 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/485 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61P 1/18 (2018.01); C07D 401/04 (2013.01); C07D 405/04 (2013.01); C07D 413/14 (2013.01); C07D 417/10 (2013.01); C07D 417/14 (2013.01); C07D 491/04 (2013.01); Y02A 50/30 (2018.01);
Abstract

Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

Find Patent Forward Citations

Loading…